19 September 2022 in Cancer Discovery
Isocitrate dehydrogenase (IDH) wild-type glioblastoma (GBM) has a dismal prognosis. A better understanding of tumor evolution holds the key to developing more effective treatment. Here we study GBM's natural evolutionary trajectory by using rare multifocal samples. We sequenced 61,062 single cells from eight multifocal IDH wild-type primary GBMs and defined a natural evolution signature (NES) of the tumor. We show that the NES significantly associates with the activation of transcription factors that regulate brain development, including MYBL2 and FOSL2. Hypoxia is involved in inducing NES transition potentially via activation of the HIF1A–FOSL2 axis. High-NES tumor cells could recruit and polarize bone marrow–derived macrophages through activation of the FOSL2–ANXA1–FPR1/3 axis. These polarized macrophages can efficiently suppress T-cell activity and accelerate NES transition in tumor cells. Moreover, the polarized macrophages could upregulate CCL2 to induce tumor cell migration. Significance: GBM progression could be induced by hypoxia via the HIF1A–FOSL2 axis. Tumor-derived ANXA1 is associated with recruitment and polarization of bone marrow–derived macrophages to suppress the immunoenvironment. The polarized macrophages promote tumor cell NES transition and migration. This article is highlighted in the In This Issue feature, p. 2711
25 February 2025 in Physics Letters A
14 December 2022 in Oncogene
25 September 2019 in Journal of Applied Physics
Plasmon-induced transparency (PIT) and plasmon-induced reflectance (PIR) are explored in a patterned graphene metamaterial using finite-difference time-domain numerical simulations and coupled-mode-theory calculations, and both PIT and PIR phenomena can be tailored dynamically by adjusting the Fermi level of graphene. Surprisingly, the group index of the proposed structure can be increased abruptly to 630, indicating ultraslow light can be achieved. Furthermore, the reflectance of the PIR can reach 70%. Therefore, the proposed structure provides a solid foundation for the realization of excellent slow-light devices, reflectors, and modulators.
8 July 2025 in Clinical Cancer Research
Purpose: High-grade glioma is the most aggressive form of primary brain tumor, characterized by rapid progression and a grim prognosis. The presence of mutations in IDH1 and TP53 is associated with a specific molecular phenotype in glioma, and their interaction is a potential target for therapy. Experimental Design: Our study utilized a combination of bioinformatics analysis, in vitro experiments, and in vivo tumor xenograft models to investigate the role of the ubiquitin-conjugating enzyme 2T (UBE2T) in the malignant progression of IDH1/TP53-mutant glioma. Results: We found that UBE2T is overexpressed in the context of TP53 mutations and is linked to enhanced glioma cell proliferation and stemness. Mechanistically, UBE2T was shown to degrade HP1α via the ubiquitin–proteasome pathway, leading to the release of the suppressive effects of R-2-hydroxyglutarate on nucleolar function and an increase in rDNA transcription. The therapeutic potential of targeting UBE2T is underscored by the discovery that APR-246, a mutant p53 reactivator, effectively suppresses UBE2T expression and reverses the hyperactivity of nucleolar transcription. Conclusions: These findings suggest that UBE2T plays a crucial role in the progression of IDH1/TP53-mutant astrocytoma and that targeting UBE2T with APR-246 could be a promising therapeutic strategy for patients with these mutations. Our study provides a foundation for further research into the role of UBE2T in glioma and the development of targeted therapies.
15 September 2026 in Neuro-Oncology
Background: Although radiation therapy (RT) remains one of the most effective treatments for patients with the lethal brain tumor glioblastoma (GBM), quite a number of patients show resistance or relapse shortly after RT. There is an urgent need to uncover the temporal and spatial dynamics of RT resistance during tumor progression and treatment. Methods: The radio-resistance signature score (RRSS) was calculated by utilizing glioma sphere-forming cells (GSCs), which recapitulate the transcriptomic landscape of GBM. Results: RRSS can assess the RT response on both cell lines and GBM patients. Both transdifferentiated and irradiated glioma cells show increased radiation resistance, demonstrating that the recurrent GBM may acquire resistance along with cell differentiation and selective advantage during treatment. Moreover, RRSS of the marginal tumors is found to be higher than that of core tumors (Wilcoxon’s rank-sum test, P-value <.01). The infiltration of macrophages was significantly associated with radiation resistance (P-value <.01), which was further validated by single-cell RNAseq-based experiments and clonogenic assays. Moreover, we demonstrated that IL1B, a pro-inflammatory cytokine secreted by macrophages, could enhance the radiation resistance of tumor cells. Conclusions: Our study revealed the spatiotemporal evolution of radiation resistance of GBM and shed light on the development of novel adjuvant therapeutic strategies.